These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8900531)

  • 1. Cancer: the interface between basic and applied research: American Association for Cancer Research Conference, Baltimore, WA; November 5-8, 1995.
    Mol Med; 1996 Jan; 2(1):21-2. PubMed ID: 8900531
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumor-infiltrating B lymphocytes as a potential source of identifying tumor antigen in human lung cancer.
    Yasuda M; Takenoyama M; Obata Y; Sugaya M; So T; Hanagiri T; Sugio K; Yasumoto K
    Cancer Res; 2002 Mar; 62(6):1751-6. PubMed ID: 11912150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell response to p53 tumor-associated antigen in patients with colorectal carcinoma.
    Bueter M; Gasser M; Schramm N; Lebedeva T; Tocco G; Gerstlauer C; Grimm M; Nichiporuk E; Thalheimer A; Thiede A; Meyer D; Benichou G; Waaga-Gasser AM
    Int J Oncol; 2006 Feb; 28(2):431-8. PubMed ID: 16391798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploiting the p53 pathway for cancer diagnosis and therapy.
    Woods YL; Lane DP
    Hematol J; 2003; 4(4):233-47. PubMed ID: 12872148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
    Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
    Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 as a potential target in cancer therapy.
    Ozturk M; Ponchel F; Puisieux A
    Bone Marrow Transplant; 1992; 9 Suppl 1():164-70. PubMed ID: 1504661
    [No Abstract]   [Full Text] [Related]  

  • 7. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer.
    Nielsen JS; Sahota RA; Milne K; Kost SE; Nesslinger NJ; Watson PH; Nelson BH
    Clin Cancer Res; 2012 Jun; 18(12):3281-92. PubMed ID: 22553348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.
    Koh J; Ock CY; Kim JW; Nam SK; Kwak Y; Yun S; Ahn SH; Park DJ; Kim HH; Kim WH; Lee HS
    Oncotarget; 2017 Apr; 8(16):26356-26367. PubMed ID: 28412752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of apoptosis, proliferating cell nuclear antigen and p53 protein in the immune response of rat colon cells to cancer and vaccination with anti-p53 polyclonal antibodies.
    Tendler Y; Ben-Hur H; Gurevich P; Berman V; Sandler B; Nyska A; Zion H; Zinder O; Zusman I
    Anticancer Res; 1997; 17(6D):4653-7. PubMed ID: 9494584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recent advances on p53 gene therapy].
    Zhang YY; Fu L
    Zhonghua Bing Li Xue Za Zhi; 2006 Jan; 35(1):48-50. PubMed ID: 16608652
    [No Abstract]   [Full Text] [Related]  

  • 11. Withaferin A induces p53-dependent apoptosis by repression of HPV oncogenes and upregulation of tumor suppressor proteins in human cervical cancer cells.
    Munagala R; Kausar H; Munjal C; Gupta RC
    Carcinogenesis; 2011 Nov; 32(11):1697-705. PubMed ID: 21859835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv.
    Xu L; Tang WH; Huang CC; Alexander W; Xiang LM; Pirollo KF; Rait A; Chang EH
    Mol Med; 2001 Oct; 7(10):723-34. PubMed ID: 11713371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.
    BioDrugs; 2003; 17(3):216-22. PubMed ID: 12749760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human papillomavirus tumor-infiltrating T-regulatory lymphocytes and P53 codon 72 polymorphisms correlate with clinical staging and prognosis of oropharyngeal cancer.
    Rittà M; Landolfo V; Mazibrada J; De Andrea M; Dell'Oste V; Caneparo V; Peretti A; Giordano C; Pecorari G; Garzaro M; Landolfo S
    New Microbiol; 2013 Apr; 36(2):133-44. PubMed ID: 23686119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TCR repertoires of intratumoral T-cell subsets.
    Linnemann C; Mezzadra R; Schumacher TN
    Immunol Rev; 2014 Jan; 257(1):72-82. PubMed ID: 24329790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restoration of wild-type p53 function in human cancer: relevance for tumor therapy.
    Bossi G; Sacchi A
    Head Neck; 2007 Mar; 29(3):272-84. PubMed ID: 17230559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic targeting of tumor suppressor genes.
    Morris LG; Chan TA
    Cancer; 2015 May; 121(9):1357-68. PubMed ID: 25557041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 Replacement Therapy for Cancer.
    Tazawa H; Kagawa S; Fujiwara T
    Recent Results Cancer Res; 2016; 209():1-15. PubMed ID: 28101684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.
    Vassilakopoulou M; Avgeris M; Velcheti V; Kotoula V; Rampias T; Chatzopoulos K; Perisanidis C; Kontos CK; Giotakis AI; Scorilas A; Rimm D; Sasaki C; Fountzilas G; Psyrri A
    Clin Cancer Res; 2016 Feb; 22(3):704-13. PubMed ID: 26408403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. iNOS expression in CD4+ T cells limits Treg induction by repressing TGFβ1: combined iNOS inhibition and Treg depletion unmask endogenous antitumor immunity.
    Jayaraman P; Alfarano MG; Svider PF; Parikh F; Lu G; Kidwai S; Xiong H; Sikora AG
    Clin Cancer Res; 2014 Dec; 20(24):6439-51. PubMed ID: 25278453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.